Cell Surface GRP78 as a Death Receptor and an Anticancer Drug Target
Abstract
:1. Introduction
2. csGRP78 as a Death Receptor
3. Natural Proapoptotic Protein Ligands of csGRP78
3.1. Prostate Apoptosis Response-4 (Par-4)
3.2. Isthmin 1 (ISM1)
3.3. Plasminogen Kringle 5 (K5)
3.4. Secreted GRP78
4. Monoclonal Antibodies as Proapoptotic Ligands of csGRP78
5. Synthetic Peptides as Proapoptotic Ligands of csGRP78
6. Conclusions and Future Perspectives
Author Contributions
Funding
Conflicts of Interest
References
- Shiu, R.P.; Pouyssegur, J.; Pastan, I. Glucose depletion accounts for the induction of two transformation-sensitive membrane proteinsin rous sarcoma virus-transformed chick embryo fibroblasts. Proc. Natl. Acad. Sci. USA 1977, 74, 3840–3844. [Google Scholar] [CrossRef] [PubMed]
- Zala, C.A.; Salas-Prato, M.; Yan, W.T.; Banjo, B.; Perdue, J.F. In cultured chick embryo fibroblasts the hexose transport components are not the 75 000 and 95 000 dalton polypeptides synthesized following glucose deprivation. Can. J. Biochem. 1980, 58, 1179–1188. [Google Scholar] [CrossRef] [PubMed]
- Lee, A.S. The glucose-regulated proteins: Stress induction and clinical applications. Trends Biochem. Sci. 2001, 26, 504–510. [Google Scholar] [CrossRef]
- Lee, A.S. Grp78 induction in cancer: Therapeutic and prognostic implications. Cancer Res. 2007, 67, 3496–3499. [Google Scholar] [CrossRef]
- Ni, M.; Zhang, Y.; Lee, A.S. Beyond the endoplasmic reticulum: Atypical grp78 in cell viability, signalling and therapeutic targeting. Biochem. J. 2011, 434, 181–188. [Google Scholar] [CrossRef]
- Vig, S.; Buitinga, M.; Rondas, D.; Crevecoeur, I.; van Zandvoort, M.; Waelkens, E.; Eizirik, D.L.; Gysemans, C.; Baatsen, P.; Mathieu, C.; et al. Cytokine-induced translocation of grp78 to the plasma membrane triggers a pro-apoptotic feedback loop in pancreatic beta cells. Cell Death Dis. 2019, 10, 309. [Google Scholar] [CrossRef]
- Shani, G.; Fischer, W.H.; Justice, N.J.; Kelber, J.A.; Vale, W.; Gray, P.C. Grp78 and cripto form a complex at the cell surface and collaborate to inhibit transforming growth factor beta signaling and enhance cell growth. Mol. Cell Biol. 2008, 28, 666–677. [Google Scholar] [CrossRef]
- Tsai, Y.L.; Ha, D.P.; Zhao, H.; Carlos, A.J.; Wei, S.; Pun, T.K.; Wu, K.; Zandi, E.; Kelly, K.; Lee, A.S. Endoplasmic reticulum stress activates src, relocating chaperones to the cell surface where grp78/cd109 blocks tgf-beta signaling. Proc. Natl. Acad. Sci. USA 2018, 115, E4245–E4254. [Google Scholar] [CrossRef]
- Philippova, M.; Ivanov, D.; Joshi, M.B.; Kyriakakis, E.; Rupp, K.; Afonyushkin, T.; Bochkov, V.; Erne, P.; Resink, T.J. Identification of proteins associating with glycosylphosphatidylinositol- anchored t-cadherin on the surface of vascular endothelial cells: Role for grp78/bip in t-cadherin-dependent cell survival. Mol. Cell Biol. 2008, 28, 4004–4017. [Google Scholar] [CrossRef]
- Quinones, Q.J.; de Ridder, G.G.; Pizzo, S.V. Grp78: A chaperone with diverse roles beyond the endoplasmic reticulum. Histol. Histopathol. 2008, 23, 1409–1416. [Google Scholar]
- Gonzalez-Gronow, M.; Selim, M.A.; Papalas, J.; Pizzo, S.V. Grp78: A multifunctional receptor on the cell surface. Antioxid. Redox Signal. 2009, 11, 2299–2306. [Google Scholar] [CrossRef] [PubMed]
- Sato, M.; Yao, V.J.; Arap, W.; Pasqualini, R. Grp78 signaling hub a receptor for targeted tumor therapy. Adv. Genet. 2010, 69, 97–114. [Google Scholar] [PubMed]
- Pizzo, S.V. Cell Surface Grp78, a New Paradigm in Signal Transduction Biology, 1st ed.; Pizzo, S.V., Ed.; Academic Press: Cambridge, MS, USA, 2018; Chapters 1–3; pp. 12–41. [Google Scholar]
- Ibrahim, I.M.; Abdelmalek, D.H.; Elfiky, A.A. Grp78: A cell’s response to stress. Life Sci. 2019, 226, 156–163. [Google Scholar] [CrossRef] [PubMed]
- Gifford, J.B.; Hill, R. Grp78 influences chemoresistance and prognosis in cancer. Curr. Drug Targets 2018, 19, 701–708. [Google Scholar] [CrossRef]
- Casas, C. Grp78 at the centre of the stage in cancer and neuroprotection. Front. Neurosci. 2017, 11, 177. [Google Scholar] [CrossRef]
- Cook, K.L.; Clarke, R. Role of grp78 in promoting therapeutic-resistant breast cancer. Future Med. Chem. 2015, 7, 1529–1534. [Google Scholar] [CrossRef]
- Bailly, C.; Waring, M.J. Pharmacological effectors of grp78 chaperone in cancers. Biochem. Pharmacol. 2019, 163, 269–278. [Google Scholar] [CrossRef]
- Guicciardi, M.E.; Gores, G.J. Life and death by death receptors. FASEB J. 2009, 23, 1625–1637. [Google Scholar] [CrossRef]
- Tsai, Y.L.; Zhang, Y.; Tseng, C.C.; Stanciauskas, R.; Pinaud, F.; Lee, A.S. Characterization and mechanism of stress-induced translocation of 78-kilodalton glucose-regulated protein (grp78) to the cell surface. J. Biol. Chem. 2015, 290, 8049–8064. [Google Scholar] [CrossRef]
- Burikhanov, R.; Zhao, Y.; Goswami, A.; Qiu, S.; Schwarze, S.R.; Rangnekar, V.M. The tumor suppressor par-4 activates an extrinsic pathway for apoptosis. Cell 2009, 138, 377–388. [Google Scholar] [CrossRef]
- Irby, R.B.; Kline, C.L. Par-4 as a potential target for cancer therapy. Expert Opin. Ther. Targets 2013, 17, 77–87. [Google Scholar] [CrossRef] [PubMed]
- Lee, A.S. The par-4-grp78 trail, more twists and turns. Cancer Biol. Ther. 2009, 8, 2103–2105. [Google Scholar] [CrossRef] [PubMed]
- Zhao, Y.; Burikhanov, R.; Brandon, J.; Qiu, S.; Shelton, B.J.; Spear, B.; Bondada, S.; Bryson, S.; Rangnekar, V.M. Systemic par-4 inhibits non-autochthonous tumor growth. Cancer Biol. Ther. 2011, 12, 152–157. [Google Scholar] [CrossRef]
- Xiang, W.; Ke, Z.; Zhang, Y.; Cheng, G.H.; Irwan, I.D.; Sulochana, K.N.; Potturi, P.; Wang, Z.; Yang, H.; Wang, J.; et al. Isthmin is a novel secreted angiogenesis inhibitor that inhibits tumour growth in mice. J. Cell Mol. Med. 2011, 15, 359–374. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Chen, M.; Venugopal, S.; Zhou, Y.; Xiang, W.; Li, Y.H.; Lin, Q.; Kini, R.M.; Chong, Y.S.; Ge, R. Isthmin exerts pro-survival and death-promoting effect on endothelial cells through alphavbeta5 integrin depending on its physical state. Cell Death Dis. 2011, 2. [Google Scholar] [CrossRef] [PubMed]
- Chen, M.; Zhang, Y.; Yu, V.C.; Chong, Y.S.; Yoshioka, T.; Ge, R. Isthmin targets cell-surface grp78 and triggers apoptosis via induction of mitochondrial dysfunction. Cell Death Differ. 2014, 21, 797–810. [Google Scholar] [CrossRef] [PubMed]
- Chen, M.; Qiu, T.; Wu, J.; Yang, Y.; Wright, G.D.; Wu, M.; Ge, R. Extracellular anti-angiogenic proteins augment an endosomal protein trafficking pathway to reach mitochondria and execute apoptosis in huvecs. Cell Death Differ. 2018, 25, 1905–1920. [Google Scholar] [CrossRef]
- Cao, Y.; Chen, A.; An, S.S.; Ji, R.W.; Davidson, D.; Llinas, M. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J. Biol. Chem. 1997, 272, 22924–22928. [Google Scholar] [CrossRef]
- Davidson, D.J.; Haskell, C.; Majest, S.; Kherzai, A.; Egan, D.A.; Walter, K.A.; Schneider, A.; Gubbins, E.F.; Solomon, L.; Chen, Z.; et al. Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78. Cancer Res. 2005, 65, 4663–4672. [Google Scholar] [CrossRef]
- McFarland, B.C.; Stewart, J., Jr.; Hamza, A.; Nordal, R.; Davidson, D.J.; Henkin, J.; Gladson, C.L. Plasminogen kringle 5 induces apoptosis of brain microvessel endothelial cells: Sensitization by radiation and requirement for grp78 and lrp1. Cancer Res. 2009, 69, 5537–5545. [Google Scholar] [CrossRef]
- Nakatsuka, A.; Wada, J.; Iseda, I.; Teshigawara, S.; Higashio, K.; Murakami, K.; Kanzaki, M.; Inoue, K.; Terami, T.; Katayama, A.; et al. Visceral adipose tissue-derived serine proteinase inhibitor inhibits apoptosis of endothelial cells as a ligand for the cell-surface grp78/voltage-dependent anion channel complex. Circ. Res. 2013, 112, 771–780. [Google Scholar] [CrossRef] [PubMed]
- Fang, S.; Hong, H.; Li, L.; He, D.; Xu, Z.; Zuo, S.; Han, J.; Wu, Q.; Dai, Z.; Cai, W.; et al. Plasminogen kringle 5 suppresses gastric cancer via regulating hif-1alpha and grp78. Cell Death Dis. 2017, 8, e3144. [Google Scholar] [CrossRef] [PubMed]
- Rondas, D.; Crevecoeur, I.; D’Hertog, W.; Ferreira, G.B.; Staes, A.; Garg, A.D.; Eizirik, D.L.; Agostinis, P.; Gevaert, K.; Overbergh, L.; et al. Citrullinated glucose-regulated protein 78 is an autoantigen in type 1 diabetes. Diabetes 2015, 64, 573–586. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Misra, U.K.; Mowery, Y.; Kaczowka, S.; Pizzo, S.V. Ligation of cancer cell surface grp78 with antibodies directed against its cooh-terminal domain up-regulates p53 activity and promotes apoptosis. Mol. Cancer Ther. 2009, 8, 1350–1362. [Google Scholar] [CrossRef]
- Misra, U.K.; Pizzo, S.V. Modulation of the unfolded protein response in prostate cancer cells by antibody-directed against the carboxyl-terminal domain of grp78. Apoptosis 2010, 15, 173–182. [Google Scholar] [CrossRef]
- de Ridder, G.G.; Ray, R.; Pizzo, S.V. A murine monoclonal antibody directed against the carboxyl-terminal domain of grp78 suppresses melanoma growth in mice. Melanoma Res. 2012, 22, 225–235. [Google Scholar] [CrossRef]
- Mo, L.; Bachelder, R.E.; Kennedy, M.; Chen, P.H.; Chi, J.T.; Berchuck, A.; Cianciolo, G.; Pizzo, S.V. Syngeneic murine ovarian cancer model reveals that ascites enriches for ovarian cancer stem-like cells expressing membrane grp78. Mol. Cancer Ther. 2015, 14, 747–756. [Google Scholar] [CrossRef]
- Lee, A.S. The er chaperone and signaling regulator grp78/bip as a monitor of endoplasmic reticulum stress. Methods 2005, 35, 373–381. [Google Scholar] [CrossRef]
- Jakobsen, C.G.; Rasmussen, N.; Laenkholm, A.V.; Ditzel, H.J. Phage display derived human monoclonal antibodies isolated by binding to the surface of live primary breast cancer cells recognize grp78. Cancer Res. 2007, 67, 9507–9517. [Google Scholar] [CrossRef]
- Liu, R.; Li, X.; Gao, W.; Zhou, Y.; Wey, S.; Mitra, S.K.; Krasnoperov, V.; Dong, D.; Liu, S.; Li, D.; et al. Monoclonal antibody against cell surface grp78 as a novel agent in suppressing pi3k/akt signaling, tumor growth, and metastasis. Clin. Cancer Res. 2013, 19, 6802–6811. [Google Scholar] [CrossRef] [Green Version]
- Lee, A.S. Glucose-regulated proteins in cancer: Molecular mechanisms and therapeutic potential. Nat. Rev. Cancer 2014, 14, 263–276. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hensel, F.; Eckstein, M.; Rosenwald, A.; Brandlein, S. Early development of pat-sm6 for the treatment of melanoma. Melanoma Res. 2013, 23, 264–275. [Google Scholar] [CrossRef] [PubMed]
- Rasche, L.; Duell, J.; Morgner, C.; Chatterjee, M.; Hensel, F.; Rosenwald, A.; Einsele, H.; Topp, M.S.; Brandlein, S. The natural human igm antibody pat-sm6 induces apoptosis in primary human multiple myeloma cells by targeting heat shock protein grp78. PLoS ONE 2013, 8, e63414. [Google Scholar] [CrossRef] [PubMed]
- Rauschert, N.; Brandlein, S.; Holzinger, E.; Hensel, F.; Muller-Hermelink, H.K.; Vollmers, H.P. A new tumor-specific variant of grp78 as target for antibody-based therapy. Lab. Invest. 2008, 88, 375–386. [Google Scholar] [CrossRef] [PubMed]
- Rasche, L.; Duell, J.; Castro, I.C.; Dubljevic, V.; Chatterjee, M.; Knop, S.; Hensel, F.; Rosenwald, A.; Einsele, H.; Topp, M.S.; et al. Grp78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin m antibody pat-sm6. Haematologica 2015, 100, 377–384. [Google Scholar] [CrossRef] [PubMed]
- Rasche, L.; Menoret, E.; Dubljevic, V.; Menu, E.; Vanderkerken, K.; Lapa, C.; Steinbrunn, T.; Chatterjee, M.; Knop, S.; Dull, J.; et al. A grp78-directed monoclonal antibody recaptures response in refractory multiple myeloma with extramedullary involvement. Clin. Cancer Res. 2016, 22, 4341–4349. [Google Scholar] [CrossRef] [Green Version]
- Arap, M.A.; Lahdenranta, J.; Mintz, P.J.; Hajitou, A.; Sarkis, A.S.; Arap, W.; Pasqualini, R. Cell surface expression of the stress response chaperone grp78 enables tumor targeting by circulating ligands. Cancer Cell 2004, 6, 275–284. [Google Scholar] [CrossRef] [Green Version]
- Miao, Y.R.; Eckhardt, B.L.; Cao, Y.; Pasqualini, R.; Argani, P.; Arap, W.; Ramsay, R.G.; Anderson, R.L. Inhibition of established micrometastases by targeted drug delivery via cell surface-associated grp78. Clin. Cancer Res. 2013, 19, 2107–2116. [Google Scholar] [CrossRef] [Green Version]
- Staquicini, D.I.; D’Angelo, S.; Ferrara, F.; Karjalainen, K.; Sharma, G.; Smith, T.L.; Tarleton, C.A.; Jaalouk, D.E.; Kuniyasu, A.; Baze, W.B.; et al. Therapeutic targeting of membrane-associated grp78 in leukemia and lymphoma: Preclinical efficacy in vitro and formal toxicity study of bmtp-78 in rodents and primates. Pharmacogenomics J. 2018, 18, 436–443. [Google Scholar] [CrossRef] [Green Version]
- Kao, C.; Chandna, R.; Ghode, A.; Dsouza, C.; Chen, M.; Larsson, A.; Lim, S.H.; Wang, M.; Cao, Z.; Zhu, Y.; et al. Proapoptotic cyclic peptide bc71 targets cell-surface grp78 and functions as an anticancer therapeutic in mice. EBioMedicine 2018, 33, 22–32. [Google Scholar] [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ge, R.; Kao, C. Cell Surface GRP78 as a Death Receptor and an Anticancer Drug Target. Cancers 2019, 11, 1787. https://doi.org/10.3390/cancers11111787
Ge R, Kao C. Cell Surface GRP78 as a Death Receptor and an Anticancer Drug Target. Cancers. 2019; 11(11):1787. https://doi.org/10.3390/cancers11111787
Chicago/Turabian StyleGe, Ruowen, and Chieh Kao. 2019. "Cell Surface GRP78 as a Death Receptor and an Anticancer Drug Target" Cancers 11, no. 11: 1787. https://doi.org/10.3390/cancers11111787